SCHEDULE 13G/A: ARK Investment Management Discloses Significant Stake in Adaptive Biotechnologies
Beneficial Ownership Report
ARK Investment Management LLC has filed an amended Schedule 13G, revealing a 6.39% beneficial ownership stake in Adaptive Biotechnologies Corp as of December 31, 2024.
Summary
- ARK Investment Management LLC, a Delaware-based investment adviser, reported beneficial ownership of 9,424,074 shares of Adaptive Biotechnologies Corp's Common Stock.
- This ownership represents 6.39% of the total class of securities outstanding.
- ARK Investment Management LLC holds sole voting power over all 9,424,074 shares.
- The firm also holds sole dispositive power over all 9,424,074 shares.
- This filing is an Amendment No. 2 to a previous Schedule 13G, indicating an update to their reported ownership position.
Sentiment
Score: 6
Explanation: The sentiment is mildly positive as the disclosure of a significant stake by a reputable investment firm like ARK Investment Management can be interpreted as a vote of confidence in the company, potentially attracting further investor interest.
Positives
- The disclosure of a significant stake by a prominent investment firm like ARK Investment Management may signal confidence in Adaptive Biotechnologies' long-term prospects.
- Increased institutional ownership can enhance a company's visibility and potentially attract further investor interest.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance.
Industry Context
The filing reflects a significant institutional investment in the biotechnology sector, a common practice for investment firms seeking exposure to innovative healthcare and life sciences companies. ARK Investment Management is known for its focus on disruptive innovation, suggesting their stake aligns with their investment thesis in the biotech space.
Stakeholder Impact
- Shareholders may view this as a positive signal, indicating institutional confidence in Adaptive Biotechnologies' value and future prospects.
- The increased institutional ownership could potentially lead to greater liquidity and stability in the stock.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end date) |
| 02/14/2025 | Date the Schedule 13G/A was signed and filed |
Keywords
Adaptive Biotechnologies, ARK Investment Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, Investment Adviser
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.